We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Haleon Plc | LSE:HLN | London | Ordinary Share | GB00BMX86B70 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 4.50 | 1.29% | 352.80 | 11,126,989 | 16:35:21 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 353.00 | 353.20 | 353.20 | 347.10 | 348.20 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Offices-holdng Companies,nec | 11.3B | 1.05B | 0.1149 | 30.72 | 31.81B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:38:08 | AT | 13,400 | 352.80 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 26/6/2024 | 13:04 | ALNC |  TOP NEWS: Haleon sells NRT business outside of US for GBP500 million |
| 26/6/2024 | 12:45 | UK RNS | Haleon PLC Divestment of NRT business outside of the US |
| 31/5/2024 | 16:47 | UK RNS | Haleon PLC Disposal of the ChapStick brand completed |
| 23/5/2024 | 17:15 | UK RNS | Haleon PLC Director/PDMR Shareholding |
| 20/5/2024 | 14:45 | UK RNS | Haleon PLC Holding(s) in Company |
| 20/5/2024 | 14:15 | UK RNS | Haleon PLC Director/PDMR Shareholding |
| 17/5/2024 | 17:30 | UK RNS | FTSE Russell Haleon |
| 17/5/2024 | 09:03 | ALNC | TOP NEWS: GSK sells remaining Haleon stake for GBP1.25 billion |
| 16/5/2024 | 17:13 | ALNC | TOP NEWS: GSK to sell remaining holding in spin-off Haleon |
| 08/5/2024 | 17:15 | UK RNS | Haleon PLC Results of Haleon 2024 Annual General Meeting |
Haleon (HLN) Share Charts1 Year Haleon Chart |
|
1 Month Haleon Chart |
Intraday Haleon Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 15:38:08 | 352.80 | 13,400 | 47,275.20 | AT |
| 2024-07-26 15:38:08 | 352.80 | 40,140 | 141,613.92 | AT |
| 2024-07-26 15:35:21 | 352.80 | 4,661,310 | 16,445,101.68 | UT |
| 2024-07-26 15:29:59 | 353.00 | 756 | 2,668.68 | AT |
| 2024-07-26 15:29:57 | 353.10 | 1 | 3.53 | AT |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Haleon Daily Update Haleon Plc is listed in the Offices-holdng Companies,nec sector of the London Stock Exchange with ticker HLN. The last closing price for Haleon was 348.30p.Haleon currently has 9,132,301,104 shares in issue. The market capitalisation of Haleon is £32,237,022,897. Haleon has a price to earnings ratio (PE ratio) of 30.72. This morning HLN shares opened at 348.20p |
Posted at 07/6/2024 00:20 by philanderer Berenberg note details..Berenberg initiated coverage of consumer health company Haleon on Wednesday with a 'buy' rating and 407.0p price target, stating that its investment case was based in part on the US launch of Eroxon, which it expects to drive better-than-expected organic sales growth of 5.8% in 2025. Berenberg said the opportunity from the US launch of Eroxon - the first-ever over-the-counter erectile dysfunction topical cream - was "substantial". It noted that among men of all ages, 20% suffer from ED, but the condition was more pronounced in older age groups, as 50% of over 40s experience ED. "Importantly, 80% of men who suffer from ED are not taking any treatment, meaning the addressable market for Eroxon is significant," it said. "We conservatively estimate that the US rollout will improve group organic sales by an average of 0.8pp in its first five years (2025-29). We note that there are already encouraging signs from the rollout of Eroxon in the UK and Belgium, with the brand gaining 20% share in its first 12 months." The bank's investment case was also based on Haleon's exposure to attractive categories that it expects to grow 4.6% in the medium term, above Berenberg's forecast sector average of 4.1%; and the stock trading on a valuation discount of 17% to key household and personal care (HPC) peers. Berenberg also noted that Haleon trades on a 12-month forward price-to-earnings of 17.3x. |
Posted at 05/6/2024 09:56 by philanderer Berenberg starts Haleon with 'buy' - price target 407 penceCould Pfizer be unloading half it's remaining stake this month ? |
Posted at 30/5/2024 16:02 by philanderer Couldn't get my usual Colgate toothpaste in Sainsbury's this week so I looked for a quick replacement and came away with a tube of Aquafresh. Very good indeed and much cheaper at 80p . And made by HLN :-) |
Posted at 20/5/2024 10:48 by alphorn There is another argument with these big holdings in that it makes it much easier for a predator to make a move.This was highlighted in the Glaxo acquisition of Wellcome; the biggest hostile acquisition in the UK at the time. The classical argument was that the large holding by the Wellcome Foundation made the Wellcome Pharma company untouchable - it was the opposite and it allowed Glaxo to move with a big promised holding under its belt. I still believe that HLN will get snapped up in time. |
Posted at 19/5/2024 10:04 by philanderer Yes, I would have thought so. This from early april.Haleon overhang can be gone in a year, suggests Barclays One of the biggest drags on the share price of consumer group Haleon might be gone by the end of the year suggests Barclays. According to the broker, and based on Pfizer's latest placing, it's possible it and GSK will have entirely sold down by the end of this year, leaving Haleon 100% free float, said the broker. “Given repeated investor feedback about the overhang being a barrier to share price performance, we think this could be a significantly helpful potential catalyst.” Currently, Pfizer has 2062m shares in Haleon (22.6%) and GSK has 385m (4.2%) for a total overhang of 27%, down from 45% in May 2023 before the first GSK placing. “The pace of sell-down is accelerating and our analysis shows Haleon could be overhang-free by year-end at the current rate of progress,” said the broker. “With a 90-day lockup from the Mar24 placing, there is time for three more placings before year-end, assuming the lockup remains unchanged. “Haleon also has £185m remaining in its announced buyback plans for this year, which is 57m shares at the current share price. This would leave an overhang of 18m shares, or 0.2% of Haleon, less than a rounding error.” Barclays sees the overhang as a key reason for Haleon’s strong sales performance since its split from GSK has failed to translate into a better share price performance. “When Haleon spun in summer 2022 there was considerable scepticism about its 4-6% organic sales growth target, yet that year it delivered 9%. “Then there was considerable scepticism about it delivering 4-6% in 2023 given the 9% comp, yet last year it delivered 8%. Barclays added that Haleon remains one of its most preferred names within European Consumer Staples, a sector it sees as highly attractive, and potentially consolidating. The broker has a price target of 390p for Haleon and an overweight rating. proactiveinvestors.c |
Posted at 19/5/2024 00:47 by pdosullivan Cheers. Not a big deal if so as presumably Pfizer will look to sell more later this year presuming the share price remains around current levels. |
Posted at 18/5/2024 18:17 by pdosullivan Has anyone seen if HLN repurchased some more of its stock as part of the final GSK sell down this week please? |
Posted at 17/5/2024 08:39 by zho GSK plc (LSE/NYSE: GSK) today announced that, further to its announcement on 16 May 2024, GSK has agreed to sell 385,320,110 ordinary shares in Haleon plc ("Haleon") at a price of 324 pence per share (the "Placing Shares"), raising gross proceeds of approximately £1,248m (the "Placing").Following settlement of the Placing, GSK will have fully exited its position and will no longer hold any ordinary shares in Haleon. |
Posted at 15/12/2023 13:45 by anhar Trailing yield is actually 1.3%. This is based on last 12m divis total 4.2p (22 final of 2.4p plus 23 interim 1.8p) on the share price of 319p. The 23 forecast is for 5.5p making a forward yield of 1.7%.Still very low though. I hold HLN acquired via the GSK demerger and what may be supporting the price, if you think there is a reason other than the normal random walk of share prices, is bid hopes, as you suggest. Everyone thinks that, making it less likely! |
Posted at 07/10/2022 10:31 by anhar Strange how the share has been rising in recent weeks, given that the lock-in overhang from GSK and PFE is public knowledge and has been ever since the demerger details were released months ago.I don't have the faintest idea of the manner in which they might dispose of their HLN shares and how it might affect the share price, but it just seems odd that if you are correct with your repetitive assertions about a price crash driven by big sales, why would the price be rising now? Big cap share prices are driven by institutional trading, small private investors like us are irrelevant. So the rising price must be driven by inst buying on balance. Why would that be if it is feared that the price would soon collapse? Surely, if your view proves anywhere near accurate, they would be better waiting for the big HLN price crash you keep mentioning. In other words their opinions must be virtually the exact opposite of yours. I''m not saying that insts are always right, they're often wrong, but it does appear odd in this situation where there's only a few weeks at stake. My view is that any potential big price fall is already in the price so there is little to fear. In any case, personally I hold shares very long term so I'm hanging on to my HLN allocation as it may prove to be a good share in years to come. Short term fears like you keep stating are of no concern to me and even if you're right, I'd see it as a buying opportunity and nothing to worry about. Nobody is going to care in several years time about a historical GSK/PFE overhang. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
